NTBLQ — Notable Labs Share Price
0.000.00%
Last trade - 00:00- $0.00m
- -$3.79m
- $0.31m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0 | ||
| Price to Tang. Book | 0 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -239.48% | ||
| Return on Equity | -126.68% | ||
| Operating Margin | -6493.61% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.56 | 0.92 | 0.77 | 0.66 | 0.31 | n/a | n/a | -11.93% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Notable Labs Ltd, formerly Vascular Biogenics Ltd, is an Israel-based clinical-stage biopharmaceutical company committed to developing next-generation, targeted medicines for difficult-to-treat medical conditions. The Company has created a pipeline of therapeutics that address cancer and immune-inflammatory diseases with the goal of significantly improving patient outcomes and overcoming the limitations of approved treatments. The Company's product candidates are built off of two platform technologies: Vascular Targeting System (VTS), a gene-based technology targeting newly formed blood vessels, and Monocyte Targeting Technology (MTT), an antibody-based technology able to specifically inhibit monocyte migration for immune-inflammatory applications.
Directors
- Bennett Shapiro NEC (81)
- Dror Harats CEO (64)
- Marc Kozin NVC (59)
- Sam Backenroth CFO
- Eyal Breitbart VOP (54)
- Erez Feige VPR (47)
- Tami Rachmilewitz VPR (51)
- Naamit Sher VPR (66)
- Ayelet Horn GCN (50)
- Amos Ron SEC (65)
- Alison Finger DRC
- Michael Rice DRC
- Ruth Alon NID (69)
- Shmuel Ben Zvi NID (60)
- Ron Cohen NID (65)
- David Hastings NID (59)
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- January 31st, 2000
- Public Since
- September 30th, 2014
- No. of Shareholders
- 138
- No. of Employees
- 16
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 9,659,496
- Address
- 320 Hatch Drive, FOSTER CITY, 94404
- Web
- https://notablelabs.com/
- Phone
- +1 4158512410
- Contact
- Daniel Ferry
- Auditors
- WithumSmith Brown PC
Upcoming Events for NTBLQ
Q2 2025 Notable Labs Ltd Earnings Release
Similar to NTBLQ
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
Adynxx
Pink Sheets on Nasdaq
FAQ
What is the Notable Labs share price?
As of Today at 22:21 UTC, shares in Notable Labs are trading at $0.00. This share price information is delayed by 15 minutes.
How has the Notable Labs share price performed this year?
Shares in Notable Labs last closed at $0.00 and the price had moved by -100% over the past 365 days. In terms of relative price strength the Notable Labs share price has underperformed the S&P500 Index by -100% over the past year.
What are the analyst and broker recommendations for Notable Labs?
The overall consensus recommendation for Notable Labs is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Notable Labs dividend yield?
Notable Labs does not currently pay a dividend.
Does Notable Labs pay a dividend?
Notable Labs does not currently pay a dividend.
When does Notable Labs next pay dividends?
Notable Labs does not currently pay a dividend.
How do I buy Notable Labs shares?
To buy shares in Notable Labs you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Notable Labs?
As of the previous close price of $0.00, shares in Notable Labs had a market capitalisation of $0.00m.
Where are Notable Labs shares listed?
Here are the trading details for Notable Labs:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: NTBLQ
What kind of share is Notable Labs?
Based on an overall assessment of its quality, value and momentum Notable Labs is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Notable Labs share price forecast for 2025?
The analyst consensus target price for shares in Notable Labs is $9.00. That is 899999900% above the last closing price of $0.00.
Analysts covering Notable Labs currently have a consensus Earnings Per Share (EPS) forecast of -$2.43 for the next financial year.
Find out moreWhat is the trend in the Notable Labs share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Notable Labs. Over the past six months, its share price has underperformed the S&P500 Index by -100%.
As of the last closing price of $0.00, shares in Notable Labs were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Notable Labs PE Ratio?
The Notable Labs PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Notable Labs?
Notable Labs' management team is headed by:
- Bennett Shapiro - NEC
- Dror Harats - CEO
- Marc Kozin - NVC
- Sam Backenroth - CFO
- Eyal Breitbart - VOP
- Erez Feige - VPR
- Tami Rachmilewitz - VPR
- Naamit Sher - VPR
- Ayelet Horn - GCN
- Amos Ron - SEC
- Alison Finger - DRC
- Michael Rice - DRC
- Ruth Alon - NID
- Shmuel Ben Zvi - NID
- Ron Cohen - NID
- David Hastings - NID